Alpha Centric Advisors LLC Neurocrine Biosciences Inc Transaction History

Alpha Centric Advisors LLC

$97.4 Million
Q4 2024

A detailed history of Alpha Centric Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 3,684 shares of NBIX stock, worth $408,445. This represents 0.52% of its overall portfolio holdings.

Number of Shares

3,684

Previous 22,500 83.63%

Holding current value

$408,445

Previous $2.59 Million 80.62%

% of portfolio

0.52%

Previous 2.19%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 31, 2025	SELL	$111.62 - $139.44 $2.1 Million - $2.62 Million	-18,816 Reduced 83.63%	3,684 $502,000
Q3 2024 Oct 30, 2024	BUY	$114.58 - $153.15 $1.78 Million - $2.37 Million	15,500 Added 221.43%	22,500 $2.59 Million
Q1 2024 Apr 24, 2024	BUY	$130.4 - $143.74 $912,800 - $1.01 Million	7,000 New	7,000 $965,000
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $611,130 - $761,150	-6,500 Reduced 17.81%	30,000 $3.38 Million
Q2 2023 Aug 08, 2023	BUY	$89.53 - $104.87 $1.88 Million - $2.2 Million	21,000 Added 135.48%	36,500 $3.44 Million
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $1.46 Million - $1.91 Million	15,500 New	15,500 $1.57 Million
Q2 2021 Mar 09, 2022	SELL	$89.43 - $102.27 $178,860 - $204,540	-2,000 Closed	0 $0
Q1 2021 Mar 09, 2022	SELL	$87.57 - $119.4 $70,056 - $95,520	-800 Reduced 28.57%	2,000 $195,000
Q4 2020 Mar 11, 2022	BUY	$86.91 - $108.33 $217,275 - $270,825	2,500 Added 833.33%	2,800 $268,000
Q3 2020 Mar 11, 2022	BUY	$96.16 - $135.15 $7,212 - $10,136	75 Added 33.33%	300 $29,000
Q2 2020 Mar 11, 2022	BUY	$85.09 - $130.36 $19,145 - $29,331	225 New	225 $27,000

Others Institutions Holding NBIX

# of Institutions

655

Shares Held

96.6M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.6B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.

Account

Alpha Centric Advisors LLC Neurocrine Biosciences Inc Transaction History